US Stock MarketDetailed Quotes
CLPT ClearPoint Neuro
- 11.410
- -0.240-2.06%
Close Nov 11 16:00 ET
314.74MMarket Cap-16536P/E (TTM)
12.225High11.260Low316.19KVolume12.200Open11.650Pre Close3.66MTurnover1.24%Turnover RatioLossP/E (Static)27.58MShares14.12552wk High10.86P/B290.09MFloat Cap5.10552wk Low--Dividend TTM25.42MShs Float31.290Historical High--Div YieldTTM8.28%Amplitude2.860Historical Low11.589Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
ClearPoint Neuro Stock Forum
Here are the companies I'm watching to potentially initiate a position in my small-cap portfolio:
Focuses on the development and manufacturing of advanced silicon-anode lithium-ion batteries that enhance the energy density and safety of portable electronics and electric vehicles.
Provides spa...
ClearPoint Neuro Congratulates Partner Aspen Neuroscience on Use of the ClearPoint® Navigation System for All Enrolled Patients in ASPIRO Clinical Trial
ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Therapy System
ClearPoint Neuro announced the full market release of its SmartFrame OR platform and ClearPoint Prism Neuro Laser Therapy System at the 2024 ASSFN meeting in Nashville from June 1-4.
The SmartFrame OR aims to expand Deep Brain Stimulation (DBS) to more hospitals, making it accessible to more patients. Dr. Kim Burchiel noted that DBS is effective for Parki...
NEWS
ClearPoint Neuro to Present Novel Research and Exhibit at the 27th American Society of Gene & Cell Therapy Annual Meeting in Baltimore
SOLANA BEACH, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it will present novel research and exhibit at the 27th American Society of Gene & Cell Therapy Annual Meeting to be hel...
ClearPoint Neuro Received FDA Clearance For Prism Bone Anchor Accessory
NEWS
ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
SOLANA BEACH, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulates its partner AviadoBio on treating its first patie...
4 MINUTES AGO, 4:05 PM EST
VIA GLOBENEWSWIRE
Moomoo 24/7· just
No comment yet